Evolution of myeloid-mediated immunotherapy resistance in prostate cancer

10.1038/s41586-024-08290-3

Affiliations
Aram Lyu, Zenghua Fan, Matthew Clark, Averey Lea, Diamond Luong, Ali Setayesh, Alec Starzinski, Rachel Wolters, Marcel Arias-Badia, Kate Allaire, Kai Wu, Vibha Gurunathan, Laura Valderrábano, Xiao X Wei, Richard A Miller, Eliezer M Van Allen, Lawrence Fong

DOI: 10.1038/s41586-024-08290-3

Abstract
Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) are refractory to immune checkpoint inhibitors (ICIs)

Keywords
mCRPC，CD3，ICIs

Produits associés

Numéro de catalogue	Nom du produit	Description	Cible
HY057507	CD3		CD3E, CD3e, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 epsilon chain, T3E

Protéines Recombinantes

Anticorps

Kits d'Essai

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer

Accès rapide

Contactez-nous